Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? (Q37222606)

19 August 2017

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? (English)

1 reference

19 August 2017

phase I clinical trial

0 references

1

S Postel-Vinay

0 references

Jorge Barriuso

object named as

J Barriuso

5

0 references

Udai Banerji

object named as

U Banerji

7

0 references

author name string

S Postel-Vinay

1

1 reference

19 August 2017

H-T Arkenau

2

1 reference

19 August 2017

D Olmos

3

1 reference

19 August 2017

J Ang

4

1 reference

19 August 2017

S Ashley

6

1 reference

19 August 2017

J De-Bono

8

1 reference

19 August 2017

I Judson

9

1 reference

19 August 2017

S Kaye

10

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

British Journal of Cancer

19 August 2017

1 reference

19 August 2017

100

1 reference

19 August 2017

9

1 reference

19 August 2017

1373-1378

1 reference

Risks and benefits associated with novel phase 1 oncology trial designs

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Ethics of phase 1 oncology studies: reexamining the arguments and data

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Clinical trial designs for cytostatic agents: are new approaches needed?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Challenges and pitfalls of combining targeted agents in phase I studies

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Phase I clinical trial design in cancer drug development

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2694416

Response rates, duration of response, and dose response effects in phase I studies of antineoplastics

3 September 2018

1 reference

12 December 2020

Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan

1 reference

12 December 2020

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

1 reference

12 December 2020

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

1 reference

12 December 2020

Dose selection in phase I studies: why we should always go for the top

1 reference

12 December 2020

Biomarkers in early clinical trials: the committed and the skeptics

1 reference

12 December 2020

Dose selection in phase I studies: why we should always go for the most effective

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6605030

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19401696

1 reference